Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Purchased by Barclays PLC

Barclays PLC lifted its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 357.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 8,837 shares of the medical instruments supplier's stock after purchasing an additional 6,905 shares during the quarter. Barclays PLC owned about 0.16% of Mesa Laboratories worth $1,148,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Canada Pension Plan Investment Board purchased a new stake in Mesa Laboratories during the second quarter worth approximately $26,000. FMR LLC lifted its holdings in shares of Mesa Laboratories by 34.1% during the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier's stock valued at $51,000 after acquiring an additional 100 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Mesa Laboratories during the 3rd quarter worth $70,000. Berry Wealth Group LP acquired a new stake in Mesa Laboratories in the 3rd quarter valued at $204,000. Finally, Amalgamated Bank increased its holdings in Mesa Laboratories by 6.5% in the 3rd quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier's stock valued at $206,000 after purchasing an additional 97 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company's stock.

Insider Transactions at Mesa Laboratories

In other news, CEO Gary M. Owens sold 2,518 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the transaction, the chief executive officer now owns 45,888 shares of the company's stock, valued at approximately $5,213,794.56. This trade represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. StockNews.com downgraded Mesa Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, November 13th. Evercore ISI increased their price objective on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st.

Mesa Laboratories Stock Down 0.0 %

NASDAQ:MLAB traded down $0.05 on Tuesday, reaching $131.05. The stock had a trading volume of 30,961 shares, compared to its average volume of 33,245. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $147.34. The stock has a market cap of $711.73 million, a P/E ratio of -2.88 and a beta of 0.82. The company has a current ratio of 0.70, a quick ratio of 0.51 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average of $124.37 and a 200 day moving average of $120.98.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, February 28th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.49%. The ex-dividend date of this dividend is Friday, February 28th. Mesa Laboratories's dividend payout ratio (DPR) is currently -1.40%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.